drugset
drugset / Trial / NCT00702403

Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML

NCT00702403 ↗

Phase 1/2 Completed 40 enrolled Fred Hutchinson Cancer Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial is studying the side effects and best way to give nilotinib when given alone or sequentially after imatinib mesylate after donor stem cell transplant in treating patients with acute lymphoblastic leukemia or chronic myelogenous leukemia. Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2008-08-14
Primary completion
2013-12
Completion
2013-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule 400 mg Oral
Subject Nilotinib Small molecule 175 mg/m2 Oral
Subject Nilotinib Small molecule 300 mg Oral

Indications

adult acute lymphoblastic leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive childhood acute lymphoblastic leukemia leukemia, myeloid, accelerated-phase